Stem Cells – The Hype & Hope – World Analysis 2009-2024

March 20, 2009 - PRLog -- Report Details
Stem cell technologies – changes to US regulations to give exciting new hopes and potentially vast commercial opportunities – brand new indepth study analysis how.
Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains. Currently, in 2009, the new US administration is lifting some major restrictions on stem cells technologies. This developmental obstacle now removed, all types of stem cells are available for expanding the therapeutic and commercial potentials, as our new report Stem Cells – The Hype & Hope – World Analysis 2009-2024 explains. Based upon the cells that create and renew all tissues potentially, stem cell therapies could revolutionise the treatment of disease, especially through tissue and organ replacement. Stem cells could provide revolutionary treatments for conditions from diabetes to multiple sclerosis, and from myocardial infarction to chronic obstructive pulmonary disease, amongst many others. Stem cell lines could also change the way pharmaceutical companies assess new chemical entities during R&D.  

A conservative estimate places the potential market value of stem cells at over $150bn by late next decade. But will stem cell products be ready to meet regulatory hurdles and market requirements? Where is stem cell research heading today? What stem cell therapies are likely to hit the market from 2009 onwards? Where does the highest value lie in the short-term? What are the commercial threats there? This new visiongain report answers these and other crucial questions about this important developing field, one with vast commercial potential.

Comprehensive analysis of the global stem cells sector and market
Stem Cells – The Hype & Hope – World Analysis 2009-2024 examines stem cells technology critically. We used a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of important contemporary issues, especially relevant commercial drivers and restraints. This report also covers regulations and ethics. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, visiongain applied rigorous financial forecasting, qualitative analyses and the assessment of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion that you will not find elsewhere.

Why you should buy this report:
Key information that you will find in Stem Cells – The Hype & Hope – World Analysis 2009-2024 includes:
Analyses of the existing market value for stem cells
Analyses of the potential market value of stem cell therapies, including detailed revenue forecasts from 2009 to 2024
Forecasts for existing stem cell markets, including private cord blood banks and Osiris Therapeutics and NuVasive’s Osteocel
Discussions of ethical complications and situations that influence the way stem cell medicine is perceived, researched and conducted
Analyses of key organisations, suppliers and relevant national laws
Expert opinions from original research interviews with key opinion leaders in stem cells research and technology
Informed analyses of the strengths and weaknesses of the technologies from 2009 onwards
Balanced assessments of commercial drivers and restraints in the stem cells field.
Visiongain believes that stem cell technologies are progressing rapidly. We predict that more products will enter the market over the coming 5 years, changing the commercial landscape for stem cells.  

You can order this report today
Nobody with an interest in the stem cells field can afford to overlook this new market study from visiongain. The market environment in many countries will change, especially after favourable developments in the US in early 2009. Visiongain predicts that revenues for stem cell technologies will increase greatly from 2009 to 2024, with important events shaping trends. Will stem cells revolutionise medicine in the foreseeable future? What are the main obstacles to overcome there? What revenues can be achieved? This report covers those vital questions and many more. Do you want to know more about this important market? You can stay ahead in this exciting field by ordering this report today.

Companies and Organisations Mentioned in this Report
Advanced Cell Technology
Alliance Technology Ventures
American Spinal Injury Association (ASIA)
Anthony Nolan Trust
Assisted Human Reproductions Agency, Canada
AstraZeneca
Athersys
Australian Stem Cell Centre
Axiogenesis AG
Barts & The London NHS Trust
Bayer Schering Pharma
Biogenea-CellGenea
Blutspendedienst Baden-Württemberg - Hessen
Boston Scientific Corp.
BrainStorm Cell Therapeutics
Calibochem
California Institute for Regenerative Medicines (CIRM)
Cambridge University Hospitals
Canadian Institute of Health
Canadian Institutes of Health Research (CIHR)
CellCure Neurosciences, Ltd.
Cellerix
Cellular Dynamics
Cellular Engineering Technologies
Centre for Cellular and Molecular Biology, India
CHA Biotech Co., Ltd, Korea
Children's Hospital & Research Center, Oakland, California
Christian Medical College, Vellore, India
Clinical Research Facility for Stem Cells and Regenerative Medicine, India
Comment on Reproductive Ethics (CORE)
Cord Blood Registry, US
Cordon Vital (CBR), Mexico
Cryo-Cell International
Cytori Therapeutics
Department of Defense (US)
Deutsches Herzzentrum Muenchen
Duke University
Eli Lilly and Company
Else Kröner Fresenius Foundation
ES Cell International, Singapore
European Group for Blood and Marrow Transplantation
European Medicines Agency (EMA)
European Union Group on Ethics (EGE)
Financiadora de Estudos e Projetos (FINEP)
Food and Drug Administration (FDA)
Franziskus-Krankenhaus
Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
Garnet BioTherapeutics
Genzyme
German Heart Institute
Geron
Guidant Corporation
Hadassah Medical Organization
Haematology Service, University Hospital of Salamanca
Harvard Biosciences, Inc.
Harvard Stem Cell Institute
Health Resources and Services Administration
Human Fertilisation and Embryology Authority (HFEA)
Imperial College London
Institute for Medical Sciences, Nizam
Instituto de Cardiologia do Rio Grande do Sul
iPS Cells
Israeli Health Ministry
Johann Wolfgang Goethe University Hospitals
Johns Hopkins University
Johnson & Johnson Development Corporation
King's College London
Kingston University, Surrey, UK
Korea Stem Cell Bank Co., Ltd. (KSCB)
Krankenhaus der Barmherzigen Brüder Trier
Leids University Medical Centre
LifeCell India
London Development Agency
London Regenerative Medicine Network (LRMN)
M.D. Anderson Cancer Center
Medical Research Council
MediStem, Inc.
Memorial Sloan-Kettering Cancer Center
Merck KGaA
Merck Serono
Miltenyi Biotec
Ministry of Health, Brazil
Ministry of Health, Iran
Ministry of Science and Higher Education, Poland
Mytogen, Inc.
National Cancer Institute (NCI)
National Marrow Donor Program
Nephros
Neuralstem, Inc.
Neuronyx
NHS Foundation Trust
Northwestern University
Northwestern University Feinberg School of Medicine, Chicago
Novartis
Novocell
NuVasive, Inc.
OSI Pharmaceuticals
Osiris Therapeutics
Parent's Guide to Cord Blood Foundation
Pfizer
Pluristem Therapeutics, Inc.
Postgraduate Institute of Medical Education and Research, India
Primogenix
ProLife Alliance
Proteus Venture Partners
Queen Mary University of London
Radius Medical, LLC
Regenetech
Reliance Life Sciences
More Companies.................

Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom

Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com

# # #

Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services.